Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis.

After 20 months of pirfenidone therapy, the patient was less symptomatic with improved effort tolerance and lung function showed a trend towards improvement (FVC 58% and DLCO 54% predicted) [Ref Table 1 and Figure 1 ].

also in 53,322 other papers